Ligand Announces Up To $47M Financing For CAR-T Developer AvenCell, Including Up To $41M For Pipeline Royalties
Share
Why It Matters
Ligand is giving money to help a CAR-T cell company grow. This shows Ligand believes in new treatments and might earn money back later.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.